Testosterone replacement in hypogonadal prostate cancer patients

There continues to be controversy over the role of testosterone replacement therapy (TRT) in men with prostate cancer who are “hypogonadal” — i.e., men with very low testosterone levels — as a consequence of their treatment. … READ MORE …

The weekend news reports: April 18, 2009

Today’s news reports deal with:

  • Active surveillance management strategies and outcomes to date
  • Life expectancy and the appropriateness of treatment
  • Penile rehabilitation post-surgery
  • Testosterone replacement therapy in prostate cancer patients … READ MORE …

The Tuesday news update: March 10, 2009

Today’s news reports include items on:

  • Risk for prostate cancer
  • Patient decisions about sexual functionality and prostate cancer treatment
  • Whole gland and focal cryotherapy
  • Testosterone replacement after prostate cancer therapy

and other items. … READ MORE …

Wednesday’s prostate cancer news: February 11, 2009

Today’s news reports contain four key items:

  • A review of the potential of phytochemicals in treatment of prostate cancer
  • A Norwegian study on correlation between biopsy-based and post-surgical Gleason scores
  • A retrospective study on risk for prostate cancer in men being treated with testosterone replacement therapy
  • An announcement of new data on PSP94 in the diagnosis of prostate cancer … READ MORE …

And the Sunday prostate cancer news: November 2, 2008

In a separate post we have addressed the clinical significance of a finding of tertiary Gleason pattern 5 in a core (or cores) following prostate needle biopsy. Other reports, addressed below, deal with:

  • Genomic markers for prostate cancer risk stratification
  • Outcomes of men with “prevalent” as opposed to “incident” prostate cancer
  • Quality of life of men diagnosed with and treated for T3-4 disease
  • Testosterone replacement therapy and risk for prostatic disease … READ MORE …

Thursday news update, Part A: October 30, 2008

There’s a lot of news today, so we will break it into two sections for reading convenience. In Part A, we deal with information about:

  • Physicial activity and prostate cancer risk
  • Vasectomy and prostate cancer risk
  • The use of surveillance and watchful waiting in men in Sweden
  • A modification to Walsh’s nerve-sparing radical prostatectomy
  • The risks of “multimodal” therapy in high-risk patients and
  • A new, long-acting form of testosterone therapy … READ MORE …